| Code | CSB-RA004847MB14HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to reference antibody S-531011, targeting CCR8 (C-C chemokine receptor type 8). CCR8 is a G protein-coupled receptor that binds the chemokine CCL1, playing a critical role in T cell trafficking and immune regulation. This receptor is preferentially expressed on regulatory T cells (Tregs) within the tumor microenvironment, where it contributes to immunosuppression and tumor immune evasion. CCR8 has emerged as a promising therapeutic target in immuno-oncology, with particular relevance to various solid tumors including colorectal, breast, and lung cancers.
S-531011 is an investigational therapeutic antibody that has been evaluated for its ability to deplete CCR8-positive Tregs in the tumor microenvironment, potentially enhancing anti-tumor immune responses. This biosimilar provides researchers with a valuable tool for investigating CCR8 biology, exploring Treg-mediated immunosuppression mechanisms, and studying potential immunotherapeutic strategies. It supports investigations into tumor immunity, chemokine receptor signaling, and the development of novel cancer immunotherapy approaches.
There are currently no reviews for this product.